Efficacy and safety of natalizumab extended interval dosing

被引：0
|
作者：
Zeineddine, M. [1 ]
Ayyoubi, N. [1 ]
Tamim, H. [2 ]
Nicolas, J. [3 ]
Khoury, S. [1 ]
Yamout, B. [1 ]
机构：
[1] Amer Univ Beirut, Med Ctr, Nehme & Therese Tohme Multiple Sclerosis Ctr, Beirut, Lebanon
[2] Clin Res Inst, Beirut, Lebanon
[3] Amer Univ Beirut, Beirut, Lebanon
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1655
引用
收藏
页码：871 / 871
页数：1
相关论文
共 50 条
  • [31] Effectiveness of natalizumab extended interval dosing in multiple sclerosis patients
    Petrzalka, M.
    Meluzinova, E.
    Mojzisova, H.
    Libertinova, J.
    Rockova, P.
    Nema, E.
    Elisak, M.
    Marusic, P.
    [J]. CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2020, 83 (01) : 79 - 83
  • [32] Population Pharmacokinetic Modeling of Natalizumab Efficacy Using Body Weight as a Classification Factor for Extended Interval Dosing
    Amarante, D.
    Muralidharan, K. K.
    Subramanyam, M.
    Evans, K.
    Steiner, D.
    Ho, P. R.
    Koendgen, H.
    Elkins, J.
    Nestorov, I.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (02) : 337 - 338
  • [33] Natalizumab extended-interval dosing in a real-life setting
    Jeantin, Lina
    de la Motte, Marine Boudot
    Deschamps, Romain
    Gueguen, Antoine
    Gout, Olivier
    Lecler, Augustin
    Papeix, Caroline
    Bensa, Caroline
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 450
  • [34] Personalized extended interval dosing of natalizumab in MS A prospective multicenter trial
    van Kempen, Zoe L. E.
    Hoogervorst, Erwin L. J.
    Wattjes, Mike P.
    Kalkers, Nynke F.
    Mostert, Jop P.
    Lissenberg-Witte, Birgit I.
    de Vries, Annick
    ten Brinke, Anja
    van Oosten, Bob W.
    Barkhof, Frederik
    Teunissen, Charlotte E.
    Uitdehaag, Bernard M. J.
    Rispens, Theo
    Killestein, Joep
    [J]. NEUROLOGY, 2020, 95 (06) : E745 - E754
  • [35] No difference in radiologic outcomes for natalizumab patients on extended interval dosing compared with standard interval dosing in ms paths
    Zhovtis-Ryerson, L.
    Naismith, R. T.
    Krupp, L.
    Charvet, L.
    Su, R.
    Fisher, E.
    De Moor, C.
    Williams, J.
    Campbell, N.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 293 - 293
  • [36] No difference in radiologic outcomes for natalizumab patients on extended interval dosing compared with standard interval dosing in MS PATHS
    Ryerson, Lana Zhovtis
    Naismith, Robert T.
    Krupp, Lauren B.
    Charvet, Leigh
    Liao, Shirley
    Fisher, Elizabeth
    De Moor, Carl
    Williams, James R.
    Licata, Stephanie
    Campbell, Nolan
    [J]. NEUROLOGY, 2021, 96 (15)
  • [37] Exploratory PML risk assessment on Extended Interval Natalizumab Dosing.
    Ryerson, Lana Zhovtis
    Foley, John
    Kister, Ilya
    Frohman, Teresa
    Pandey, Krupa
    Lu, Xiaochun
    Goldberg, Judith
    Zuniga-Estrada, Guadalupe
    Hoyt, Tammy
    Jacob, April
    Bacon, Tamar
    Major, Eugene
    Frohman, Elliot
    [J]. NEUROLOGY, 2017, 88
  • [38] Extended dosing interval reduces risk of natalizumab-related PML
    [J]. Reactions Weekly, 2019, 1772 (1) : 9 - 9
  • [39] Real world effectiveness of Natalizumab extended interval dosing in a French cohort
    Pelle, J.
    Briant, A.
    Lebrun-Frenay, C.
    Cohen, M.
    Mondot, L.
    De Seze, J.
    Bigaut, K.
    Collongues, N.
    Kremer, L.
    Ricard, D.
    Bompaire, F.
    Sallansonnet-Froment, M.
    Ohlmann, C.
    Ciron, J.
    Biotti, D.
    Pignolet, B.
    Parienti, J.
    Defer, G.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 207 - 207
  • [40] Mri activity and extended interval of natalizumab dosing: a multicenter italian study
    Clerico, M.
    De Mercanti, S. F.
    Signori, A.
    Iudicello, M.
    Cordioli, C.
    Signoriello, E.
    Lus, G.
    Bonavita, S.
    Lavorgna, L.
    Maniscalco, G. T.
    Curti, E.
    Lorefice, L.
    Cocco, E.
    Nociti, V.
    Mirabella, M.
    Baroncini, D.
    Mataluni, G.
    Landi, D.
    Petruzzo, M.
    Lanzillo, R.
    Gandoglia, I.
    Laroni, A.
    Frangiamore, R.
    Sartori, A.
    Cavalla, P.
    Costantini, G.
    Sormani, M. P.
    Capra, R.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 538 - 538
12345